|
Re: Zenith and Pfizer collaboration news
|
2
|
Zenith Epigenetics
|
Nov 20, 2018 09:14AM
|
|
Re: Zenith and Pfizer collaboration news
|
3
|
Resverlogix Corp.
|
Nov 20, 2018 10:05AM
|
|
Re: Zenith Announces Corporate Update Conference Call & Webcast on June 18, 2020 and US$5 Million Equity Investment
|
8
|
Zenith Epigenetics
|
Jun 16, 2020 08:08AM
|
|
Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
|
3
|
Zenith Epigenetics
|
Oct 09, 2024 09:07AM
|
|
Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
|
9
|
Zenith Epigenetics
|
Sep 27, 2024 09:08AM
|
|
Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
|
3
|
Zenith Epigenetics
|
Oct 15, 2024 04:23PM
|
|
Re: Zenith down 50% this morning in US
|
6
|
Zenith Epigenetics
|
Jun 12, 2021 07:14AM
|
|
Re: Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs
|
7
|
Zenith Epigenetics
|
Jul 29, 2020 03:22PM
|
|
Re: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
|
6
|
Zenith Epigenetics
|
May 17, 2022 08:06AM
|
|
Re: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
|
1
|
Zenith Epigenetics
|
May 19, 2024 08:53PM
|
|
Re: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
|
1
|
Zenith Epigenetics
|
May 20, 2024 08:30PM
|
|
Re: Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
|
4
|
Zenith Epigenetics
|
Mar 18, 2019 01:01PM
|
|
Re: Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
|
4
|
Zenith Epigenetics
|
Mar 18, 2019 02:39PM
|
|
Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
|
5
|
Zenith Epigenetics
|
Feb 19, 2022 04:31PM
|
|
Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
|
3
|
Zenith Epigenetics
|
Feb 16, 2022 07:36AM
|
|
Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
|
3
|
Zenith Epigenetics
|
Feb 10, 2022 08:31AM
|
|
Re: Zenith Epigenetics Proudly Supports Rare Disease Day ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications Calgary, Alberta--(N
|
4
|
Zenith Epigenetics
|
Mar 01, 2024 07:04AM
|
|
Re: Zenith Epigenetics Proudly Supports Rare Disease Day ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications Calgary, Alberta--(N
|
5
|
Zenith Epigenetics
|
Mar 01, 2024 01:25PM
|
|
Re: Zenith Epigenetics Proudly Supports Rare Disease Day ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications Calgary, Alberta--(N
|
4
|
Zenith Epigenetics
|
Feb 29, 2024 11:09AM
|
|
Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
|
|
Zenith Epigenetics
|
Jun 22, 2022 07:19AM
|
